Securities Offered in This Offering
10,000,000 shares of our common stock
$1.00 per share
Common Stock to be Outstanding After This Offering
Use of Proceeds
We intend to use the net proceeds from this offering primarily for the development of our lead product candidate, oliceridine, and for other general corporate purposes.
Trevena verliert "breakthrough designation" der FDA